Firebrick Pharma Ltd (ASX: FRE) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Firebrick Pharma Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $11.13 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 195.31 million
Earnings per share -0.027
Dividend per share N/A
Year To Date Return 14.00%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Firebrick Pharma Ltd (ASX: FRE)
    Latest News

    Concept image of a man in a suit with his chest on fire.
    Share Market News

    Why is the Firebrick Pharma share price blazing 28% on Wednesday?

    Firebrick shares are having a strong day on Wednesday...

    Read more »

    A graph ablaze with fire going up, indicating a fired up and surged share price
    Share Gainers

    On fire! Firebrick (ASX:FRE) share price surges another 22% on second day of trade

    Investors are bidding up the share price of this pharmaceutical small-cap today...

    Read more »

    Vanadium Resources share price person riding rocket indicating share price increase
    IPOs

    Firebrick Pharma (ASX:FRE) share price launches 165% following ASX IPO

    The market has enthusiastically welcomed the pharmaceutical development firm.

    Read more »

    Female scientist working in laboratory for Race Oncology
    IPOs

    Firebrick Pharma (ASX:FRE) is floating on the ASX today. Here's what you need to know

    Here are all the details on the stock set to hit the ASX this afternoon.

    Read more »

    FRE ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Firebrick Pharma Ltd

    Firebrick Pharma Ltd is an Australian pharmaceutical developer. It is engaged in the development and commercialization of Nasodine, a broad-spectrum anti-viral spray, designed to be an effective treatment and prevention of respiratory viral infections such as the common cold.

    FRE Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    21 Jun 2024 $0.06 $0.00 0.00% 255,172 $0.06 $0.06 $0.06
    20 Jun 2024 $0.06 $0.00 0.00% 369,668 $0.06 $0.06 $0.06
    19 Jun 2024 $0.06 $0.00 0.00% 522,354 $0.06 $0.06 $0.06
    18 Jun 2024 $0.06 $0.00 0.00% 276,085 $0.06 $0.06 $0.06
    17 Jun 2024 $0.06 $-0.01 -14.93% 48,026 $0.07 $0.07 $0.06
    14 Jun 2024 $0.07 $0.00 0.00% 157,701 $0.07 $0.07 $0.07
    13 Jun 2024 $0.07 $0.01 16.95% 427,738 $0.07 $0.07 $0.07
    12 Jun 2024 $0.06 $0.00 0.00% 37,227 $0.06 $0.06 $0.06
    11 Jun 2024 $0.06 $0.00 0.00% 320,747 $0.06 $0.06 $0.06
    07 Jun 2024 $0.06 $0.00 0.00% 175,736 $0.06 $0.06 $0.06
    06 Jun 2024 $0.06 $0.00 0.00% 112,142 $0.06 $0.06 $0.06
    05 Jun 2024 $0.06 $0.00 0.00% 20,000 $0.06 $0.06 $0.06
    04 Jun 2024 $0.06 $0.00 0.00% 182,959 $0.06 $0.06 $0.06
    03 Jun 2024 $0.06 $0.00 0.00% 194,578 $0.06 $0.06 $0.06
    31 May 2024 $0.06 $0.00 0.00% 25,004 $0.06 $0.06 $0.06
    30 May 2024 $0.06 $0.00 0.00% 107,421 $0.06 $0.06 $0.06
    29 May 2024 $0.06 $0.00 0.00% 41,364 $0.06 $0.06 $0.06
    28 May 2024 $0.06 $-0.01 -14.29% 324,137 $0.06 $0.06 $0.06
    27 May 2024 $0.07 $0.00 0.00% 7,466 $0.07 $0.07 $0.07
    24 May 2024 $0.07 $0.00 0.00% 97,778 $0.07 $0.07 $0.07
    23 May 2024 $0.07 $0.00 0.00% 92,131 $0.07 $0.07 $0.07

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Peter Laurence Molloy FounderChief Executive OfficerExecutive ChairmanExecutive Director Apr 2012
    Dr Molloy was a Managing Director of Australia/NZ operations and later Vice President for Strategic Marketing, responsible for the marketing of hundreds of pharmaceuticals across 22 countries. During his pharmaceutical career, he has directly launched 23 new pharmaceutical products and executed 40 international licensing or distribution deals., As CEO of four biotech companies, he has led R&D programs, moved several drugs from research into human clinical trials, and executed valuable international pharmaceutical partnerships including two $100m+ licensing deals. In 2002-2005, Dr Molloy was CEO of one of the world's leading antiviral research companies, Biota Holdings Limited. Dr Molloy was responsible for the creation and launch in Australia of Betadine Sore Throat Gargle, which subsequently became a leading OTC product in Australia and the inspiration for the development of Nasodine. Dr Molloy is a founder of Firebrick and co-inventor on all the key Firebrick patents
    Dr Stephen Francis Goodall FounderChief Operating OfficerExecutive Director Apr 2012
    Dr Goodall has a track record in intellectual property, pharmaceutical development, manufacturing, regulatory strategy and clinical development. He was instrumental in developing the intellectual property that underpins the Firebrick patent. Previously, he was Chief Operating Officer of Viralytics. Previously, he was the Director of Pharmaceutical Development at Vapotronics, where he managed all aspects of inhaled drug development and formulation and before that, Director of Development at AGEN Biomedical for 11 years. He has experience in the preclinical, IND, regulatory and human clinical phases of drug development. He also has an impressive background in process development, production scale-up and GMP manufacturing for pharmaceuticals. Dr Goodall is a founder of Firebrick and co-inventor on all the key Firebrick patents.
    Dr Richard Spencer Treagus Non-Executive Director Jun 2022
    Dr Treagus after a period as Medical Director for Wyeth-Ayerst (now Pfizer), in 1998 he became Commercial Director of Aspen Pharmacare in South Africa, where he was responsible for all sales, marketing and business development for pharmacy and consumer products. Between 2002 and 2006, he was General Manager of Sigma Pharmaceuticals in Melbourne, responsible for all sales, marketing and business development, then from 2006 to 2012 was Managing Director and CEO of Acrux (ACR), the market value of which increased 10-fold during his tenure. Between 2013 and 2020, he was Executive Chairman of Neuren Pharmaceuticals (NEU), and its market value increased 6-fold during his tenure
    Dr Phyllis Irene Gardner Non-Executive Director Nov 2020
    Dr Gardner is Professor of Medicine at Stanford University and is an accomplished scientist, entrepreneur and venture capitalist, and has been a director of many prominent public biotechnology companies in the United States.
    Mr Stephen Buckley Company Secretary
    -
    Stephen Buckley Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Aquarico Pty Ltd <P & C Molloy Family A/C> 30,326,472 17.21%
    Biotech Design Pty Ltd 30,326,472 17.21%
    Zero Nominees Pty Ltd 6,391,000 3.63%
    BNP Paribas Noms Pty Ltd <DRP> 3,250,017 1.84%
    BNP Paribas Nominees Pty Ltd HUB24 Custodial Serv Ltd <DRP A/C> 3,148,844 1.79%
    Mr Ivan Kaufman 2,550,000 1.45%
    Kashflow 18 LLC 2,103,713 1.19%
    Dr Jonathan Bryden Dalitz & Mrs Michelle Anne Dalitz <Dalitz Super Fund A/C> 2,000,000 1.13%
    Mr Richard Friedland 1,840,000 1.04%
    Mr Paul Hartley Watts 1,700,000 0.96%
    GZ Family Holdings Pty Ltd <GZ Family A/C> 1,700,000 0.96%
    Ms Helen Frances Morgan 1,550,000 0.88%
    BT Portfolio Services Limited <Warrell Holdings S/F A/C> 1,500,000 0.85%
    Greensea Investments Pty Ltd 1,400,000 0.79%
    Citicorp Nominees Pty Limited 1,344,328 0.76%
    Mr Andrew John Mccormack 1,202,000 0.68%
    Netwealth Investments Limited <Wrap Services A/C> 1,185,937 0.67%
    Tubechangers Pty Ltd <King Family A/C> 1,100,000 0.62%
    Greenford Pty Ltd <Kluger Super Fund A/C> 1,040,000 0.59%
    Dr Simon Peter Tucker 1,000,000 0.57%

    Profile

    since

    Note